Zelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) immunotherapies, announced the appointment of Jens-Peter Marschner as chief medical officer (CMO) at the end of June.

Outgoing EU Commissioner for Agriculture Paul Hogan said in April, that the European Commission will exclude member states from the future Common Agricultural Policy (CAP) that do not include the promotion of the bioeconomy in agriculture.

German researchers have found a way to curb the activity of CAR T cells, even while keeping their cancer-fighting properties intact.

Galapagos’s mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary healthy andpatient cells, the company discovers which proteins play a key role in diseases such as rheumatoid arthritis, inflammatory bowel disease, and fibrosis.

Oncovita has been granted the exclusive license to an immuno-oncolytic measles virus platform developed by the Institut Pasteur. Based on the technology, the Paris-based biotech plans to develop cancer therapies.

Swedenbio’s Board has appointed Helena Strigård as the new CEO. Strigård will take up the position on September 1 and replace Jonas Ekstrand,

Teckro today announced five significant appointments to its leadership team. The hires follow Teckro’s Series C funding announcement in February, featuring investment from major US venture capital firms. To date, Teckro has raised $43 million.

Boehringer Ingelheim has licenced a preclinical fusion protein from Korean Yuhan Corp. that activates both GLP-1R and FGF21R to treat Nonalcoholic Steatohepatitis (NASH). Boehringer Ingelheim will pay $40m upfront and in near-term payments to acquire the commercialisation rights to the compound. Under the agreement, Yuhan Corp. is eligible to receive up to USD 830 million in potential milestone payments plus tiered royalties on future net sales.

A French-Swiss research team is developing a smart bra for detecting breast cancer more accessible than through mammography.

The European Council, the European Parliament, and the outgoing European Commission have agreed upon the priorities and structure of Horizon Europe (2021 to 2027), the next seven-year research and innovation programme of the European Union. This autumn, they will decide on the Parliament’s proposal to increase its budget from €100bn to €120bn.